New drug shows promise for nasal polyps in chinese patients
NCT ID NCT05878093
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug dupilumab in 63 Chinese adults with chronic sinusitis and nasal polyps. Participants received either dupilumab injections or a placebo, plus a standard nasal steroid spray, for 24 weeks. The main goal was to see if dupilumab could shrink nasal polyps and improve congestion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (injectable drug) plus budesonide nasal spray
What this could lead to
If successful, this could provide a new treatment option for Chinese adults with nasal polyps that reduces polyp size and eases congestion.
What could go wrong
This is a small Phase 3 trial (63 participants) and results may not apply to all patients. Dupilumab can cause injection site reactions and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 1560001
Beijing, 100730, China
-
Investigational Site Number : 1560004
Hangzhou, 310003, China
-
Investigational Site Number : 1560005
Beijing, 100044, China
-
Investigational Site Number : 1560006
Hefei, 230001, China
-
Investigational Site Number : 1560007
Wuhan, 430022, China
-
Investigational Site Number : 1560009
Yantai, 264000, China
-
Investigational Site Number : 1560010
Chengdu, 610041, China
-
Investigational Site Number : 1560011
Guangzhou, China
-
Investigational Site Number : 1560012
Guangzhou, 510163, China
-
Investigational Site Number : 1560013
Qingdao, China
-
Investigational Site Number : 1560014
Chongqing, 400016, China
-
Investigational Site Number : 1560016
Jinan, 250102, China
-
Investigational Site Number : 1560017
Shanghai, 200065, China
-
Investigational Site Number : 1560018
Taiyuan, 030001, China
-
Investigational Site Number : 1560020
Zibo, 255036, China
-
Investigational Site Number : 1560021
Wuhan, 430060, China
-
Investigational Site Number : 1560022
Fuzhou, 350005, China
-
Investigational Site Number : 1560025
Jingzhou, 434020, China